logo

For the Inventor, By the Inventor

Alzenau, Germany

Karl Schönafinger

This inventor holds 3 USPTO granted patents. Top assignee: Aventis Pharma Deutschland, Gmbh. Active years: 2002-2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Karl Schönafinger. Retrieved from https://idiyas.com/inventor/karl-schandoumlnafinger

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3

% Patents Active = 100.0

Average Co-Inventor Count = 3.3

ph-index = 2

Forward Citations = 58(Granted Patents)


Company Filing History:

goldMedal3 out of 330 
 
Aventis Pharma Deutschland, Gmbh
 patents

Years Active: 2002-2003

Loading Chart...
3 patents (USPTO):Explore Patents
1. 6660746 - Substituted 4-amino-2-aryl-tetrahydoquinazolines, their preparation, their use and pharmaceutical preparations comprising them (2003-12-09),
2. 6613772 - Substituted 2-aryl-4-amino-chinazolines, method for the production and use thereof as medicaments (2003-09-02),
3. 6335334 - Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them (2002-01-01),

Title: Karl Schönafinger: Innovator in Pharmaceutical Chemistry

Introduction

Karl Schönafinger is a notable inventor based in Alzenau, Germany. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 3 patents. His work focuses on the development of innovative compounds that have potential applications in medicine.

Latest Patents

Among his latest patents are:

1. Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use, and pharmaceutical preparations comprising them.

2. Substituted 2-aryl-4-amino-chinazolines, method for the production and use thereof as medicaments.

These patents reflect his commitment to advancing pharmaceutical science and improving therapeutic options.

Career Highlights

Karl Schönafinger is currently employed at Aventis Pharma Deutschland GmbH, where he continues to innovate and contribute to the development of new medications. His expertise in pharmaceutical chemistry has positioned him as a valuable asset in the industry.

Collaborations

Throughout his career, Karl has collaborated with esteemed colleagues, including Ursula Schindler and Hartmut Strobel. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Karl Schönafinger's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an influential inventor in the field. His work continues to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…